Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
modified XELIRI
- Development stage
- Phase 4
- Lead developer
- Chugai Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Modified XELIRI (mXELIRI) is a combination chemotherapy regimen consisting of capecitabine and irinotecan, used primarily in the treatment of metastatic colorectal cancer and also studied in advanced gastric cancer. The "modified" aspect refers to reduced or adjusted dosing compared to the original XELIRI protocol, aiming to improve tolerability while maintaining efficacy. Capecitabine is an oral prodrug that is converted into 5-fluorouracil (5-FU) in the body, inhibiting thymidylate synthase and interfering with DNA synthesis. Irinotecan is a topoisomerase I inhibitor that prevents DNA unwinding and replication by stabilizing the cleavable complex between topoisomerase I and DNA, leading to cell death. Modified XELIRI has demonstrated non-inferior efficacy compared to FOLFIRI regimens in phase III trials for second-line treatment of metastatic colorectal cancer, with improved convenience due to oral administration of capecitabine and a favorable safety profile[1][3][4][5].
- Other names
- capecitabine plus irinotecan (modified regimen)mXELIRI
02
Targets
TS (Thymidylate synthase)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on modified XELIRI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on modified XELIRI.